Duchenne muscular dystrophy

D Duan, N Goemans, S Takeda, E Mercuri… - Nature reviews disease …, 2021 - nature.com
Duchenne muscular dystrophy is a severe, progressive, muscle-wasting disease that leads
to difficulties with movement and, eventually, to the need for assisted ventilation and …

Skeletal muscle: A review of molecular structure and function, in health and disease

K Mukund, S Subramaniam - Wiley Interdisciplinary Reviews …, 2020 - Wiley Online Library
Decades of research in skeletal muscle physiology have provided multiscale insights into
the structural and functional complexity of this important anatomical tissue, designed to …

Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis

S Crisafulli, J Sultana, A Fontana, F Salvo… - Orphanet journal of rare …, 2020 - Springer
Abstract Background Duchenne Muscular Dystrophy (DMD) is a rare disorder caused by
mutations in the dystrophin gene. A recent systematic review and meta-analysis of global …

Antisense oligonucleotides: the next frontier for treatment of neurological disorders

C Rinaldi, MJA Wood - Nature Reviews Neurology, 2018 - nature.com
Antisense oligonucleotides (ASOs) were first discovered to influence RNA processing and
modulate protein expression over two decades ago; however, progress translating these …

Emerging therapies for Duchenne muscular dystrophy

T Markati, M Oskoui, MA Farrar, T Duong… - The Lancet …, 2022 - thelancet.com
Duchenne muscular dystrophy is an X-linked disease caused by the absence of functional
dystrophin in the muscle cells. Major advances have led to the development of gene …

Global prevalence of Duchenne and Becker muscular dystrophy: a systematic review and meta-analysis

N Salari, B Fatahi, E Valipour, M Kazeminia… - Journal of orthopaedic …, 2022 - Springer
Background A variety of mutations in the largest human gene, dystrophin, cause a spectrum
from mild to severe dystrophin-associated muscular dystrophies. Duchenne (DMD) and …

Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy

DE Frank, FJ Schnell, C Akana, SH El-Husayni… - Neurology, 2020 - neurology.org
Objective To report safety, pharmacokinetics, exon 53 skip**, and dystrophin expression
in golodirsen-treated patients with Duchenne muscular dystrophy (DMD) amenable to exon …

The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review

S Ryder, RM Leadley, N Armstrong… - Orphanet journal of rare …, 2017 - Springer
Abstract Background Duchenne Muscular Dystrophy (DMD) is a rapidly progressive, lethal
neuromuscular disorder, present from birth, which occurs almost exclusively in males. We …

The TREAT‐NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations

CL Bladen, D Salgado, S Monges… - Human …, 2015 - Wiley Online Library
Analyzing the type and frequency of patient‐specific mutations that give rise to Duchenne
muscular dystrophy (DMD) is an invaluable tool for diagnostics, basic scientific research …

Efficacy and safety of vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial

M Guglieri, PR Clemens, SJ Perlman, EC Smith… - JAMA …, 2022 - jamanetwork.com
Importance Corticosteroidal anti-inflammatory drugs are widely prescribed but long-term use
shows adverse effects that detract from patient quality of life. Objective To determine if …